Recently, lenalidomide was tested in IPSS intermediate-2- and high-risk MDS
Lately, lenalidomide was tested in IPSS intermediate-2- and high-risk MDS with del(5q), with a reduce 28 general response in our knowledge, and 36 in the Nordic MDS group’s experience.14,15 However,…